Table 2.

Anti-tumor activity of anlotinib plus TP regime in the first-line therapy for ESCC

Best responses	All patients (n = 46)
CR	4 (8.7%)
PR	31 (67.4%)
SD	7 (15.2%)
PD NE	0 4 (8.7%)
ORR	35 (76.1%, 61.2–87.4%)
DCR	42 (91.3%, 79.2–97.6%)

Data are presented as n (%) or n (%, 95% confidence interval)

CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, DCR disease control rate